Evidence map›Paper›PMID 41338303›Full record

ArticleAntiviral research2026

Novel computational pipeline to identify target sites for broad spectrum antiviral drugs.

John D Sears, Konstantin I Popov, Paul A Sylvester, Rebekah Dickmander, Jennifer Diaz, Che-Kang Chang, Julia Huff, Wes Sanders, Nicholas A Saba, Madeleine Sorensen and 9 more

Abstract read
In one paragraph

Article in Antiviral research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

John D SearsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Konstantin I PopovUniversity of North Carolina at Chapel Hill, Division of Chemical Biology & Medicinal Chemistry and Center for Integrative Chemical Biology & Drug Discovery, Eshelman School of Pharmacy, Chapel Hill, NC, 25799, United States of America.
Paul A SylvesterDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Rebekah DickmanderDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Jennifer DiazDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Che-Kang ChangDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Julia HuffDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Wes SandersDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Nicholas A SabaDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America.
Madeleine SorensenUniversity of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, CO, 80045, United States of America.
Adam M DrobishUniversity of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, CO, 80045, United States of America.
Nicholas A MayUniversity of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, CO, 80045, United States of America.
Kevin NamitzPennsylvania State University Huck Institute of Life Sciences, University Park, PA, 16802, United States of America.
Julia FeckoPennsylvania State University Huck Institute of Life Sciences, University Park, PA, 16802, United States of America.
Neela H YennawarPennsylvania State University Huck Institute of Life Sciences, University Park, PA, 16802, United States of America.
Thomas E MorrisonUniversity of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, CO, 80045, United States of America.
Alexander TropshaUniversity of North Carolina at Chapel Hill, Division of Chemical Biology & Medicinal Chemistry and Center for Integrative Chemical Biology & Drug Discovery, Eshelman School of Pharmacy, Chapel Hill, NC, 25799, United States of America.
Mark T HeiseDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America. Electronic address: mark_heisem@med.unc.edu.
Nathaniel J MoormanDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States of America; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599 United States of America. Electronic address: nmoorman@med.unc.edu.

Funding

Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Enabling the Accelerated Discovery of Novel Chemical Probes by Integration of Crystallographic, Computational, and Synthetic Chemistry ApproachesR01GM140154 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TROPSHA, ALEXANDER, WILLSON, TIMOTHY M · 2021 to 2024
$2.4M
X-ray instrumentation upgrade for single crystal diffraction and solution small angle scatteringS10OD028589 · OD · PENNSYLVANIA STATE UNIVERSITY, THE · PI YENNAWAR, NEELA H. · 2020 to 2020
$600k
Beckman Optima Multiwavelength Analytical UltracentrifugeS10OD032215 · OD · PENNSYLVANIA STATE UNIVERSITY, THE · PI YENNAWAR, NEELA H. · 2022 to 2022
$512k
Macromolecular X-Ray Crystallography InstrumentS10RR023439 · NCRR · PENNSYLVANIA STATE UNIVERSITY, THE · PI YENNAWAR, NEELA H. · 2007 to 2007
$500k
Wyatt SEC-MALS systemS10OD030490 · OD · PENNSYLVANIA STATE UNIVERSITY, THE · PI YENNAWAR, NEELA H. · 2021 to 2021
$273k
TA Instruments Low Volume AutoAffinity ITCS10OD025145 · OD · PENNSYLVANIA STATE UNIVERSITY, THE · PI YENNAWAR, NEELA H. · 2018 to 2018
$247k
NCRR NIH HHS S10 RR023439NIAID NIH HHS T32 AI007419NIGMS NIH HHS R01 GM140154NIH HHS S10 OD025145NIH HHS S10 OD028589NIH HHS S10 OD030490NIH HHS S10 OD032215
6 · The paper itself

Abstract

Emerging viruses pose an ongoing threat to human health. While certain viral families are common sources of outbreaks, predicting the specific virus within a family that will cause the next outbreak or pandemic is not possible, creating an urgent need for broad spectrum antiviral drugs that are effective against a wide array of related viral pathogens. However, broad spectrum drug development is hindered by the lack of detailed knowledge of compound binding sites that are structurally and functionally conserved between viral family members and are essential for virus replication. To overcome this limitation, we developed an in silico approach that combines AI-driven protein structure prediction, computational fragment soaking, multiple sequence alignment, and protein stability calculations to identify highly conserved target sites that are both solvent-accessible and conserved. We applied this approach to the Togaviridae family, which includes emerging pandemic disease threats such as chikungunya and Venezuelan equine encephalitis virus for which there are currently no approved antiviral therapies. Our analysis identified multiple solvent accessible and structurally conserved pockets in the alphavirus non-structural protein 2 (nsP2) protease domain, which is essential for processing the viral replicase proteins. Mutagenesis of key solvent accessible and conserved residues identified novel pockets that are essential for the replication of multiple alphaviruses, validating these pockets as potential antiviral target sites for nsP2 inhibitors. These findings highlight the potential of artificial intelligence-informed modeling for revealing functionally conserved, accessible pockets as a means of identifying potential target binding sites for broadly active direct acting antivirals.

Indexed as

Antiviral AgentsComputational BiologyBinding SitesComputer SimulationDrug DiscoveryHumansModels, MolecularSequence AlignmentViral Nonstructural ProteinsVirus ReplicationAntiviral AgentsViral Nonstructural ProteinsalphavirusesBroad spectrumProteaseTarget identificationTarget validation

Identifiers

PMID41338303
PMCPMC13484704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.